Table 3.
Average NAb to vaccine viruses and heterologous subtype-A FIV viruses a,b.
| FIV Strain (Subtype) c | Location of FIV Isolation | Ave Fel-O-Vax NAb Titer (% Responder) d | Ave IWV NAb Titer (% Responder) d | Combined % Preventable Fraction | |
|---|---|---|---|---|---|
| Fel-O-Vax d | IWV d | ||||
| FIV-Pet (A) | Petaluma CA, U.S. | 216 (63%) | 118 (83%) | 100% | 100% |
| FIV-Shi (D) | Shizuoka, Japan | 60 (74%) | 96 (78%) | 100% b | -- |
| FIV-Dix (A) | Dixon CA, U.S. | -- | 80 (70%) b | -- | -- |
| FIV-U.S.(A) | U.S. | -- | -- | 68.5% | -- |
| FIV-UK8 (A) | Glasgow, UK | 10 (30%) | 10 (13%) | 0% | 40% |
| FIV-Dutch (A) | Netherland | -- | -- | 85.6% | -- |
| FIV-Bang (A/B) | Boston, MA, U.S. | 22 (70%) | 73 (61%) | 25.0% | 71.4% |
| FIV-FC1 (B) | Florida, U.S. | 10 (30%) | 10 (13%) | 71.8–75.0% | 100% |
| FIV-MD (B) | Maryland, U.S. | 20 (62%) b | 10 (36%) b | -- | -- |
| FIV-Ao2 (B) | Aomori, Japan | -- | -- | 100% b | -- |
| FIV-NZ1 (F′/C) | New Zealand | 10 (20%) | <5 (0%) | 40.0% | 75.0% |
aTable 3 is the summary of Table 1 with emphasis on NAb titers generated by Fel-O-Vax® FIV vaccine and prototype IWV vaccine. b Additional data provided are on the average NAb titers to FIVDix [55] and to FIVMD [49], and on the dual-subtype FIVPet-ICV/FIVShi-ICV vaccine against FIVShi challenge [60]. c Vaccine strains (bolded). d Substantial NAb titers (bolded) or significant percent preventative fraction (bolded) when p < 0.05; Not available (--).